2025
Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs
Dong C, Zhang F, He E, Ren P, Verma N, Zhu X, Feng D, Cai J, Zhao H, Chen S. Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs. Patterns 2025, 6: 101184. DOI: 10.1016/j.patter.2025.101184.Peer-Reviewed Original ResearchParalogous gene pairsParalogous pairsChimeric antigen receptor T cellsResponse to cancer immunotherapyDouble knockoutCancer immunotherapy responseGene pairsCheckpoint blockadeGenome-wide screenImmunotherapy efficacyCancer immunotherapyEnhance immunotherapyImmunotherapy responseImmunotherapy effectT cellsImmunotherapyCancer treatmentIndividual genesCRISPR screensEnrichment analysisParalogsCancerTreatmentCombined targetFunctional significanceEngineering Mice to Study Human Immunity.
Sefik E, Xiao T, Chiorazzi M, Odell I, Zhang F, Agrawal K, Micevic G, Flavell R. Engineering Mice to Study Human Immunity. Annual Review Of Immunology 2025 PMID: 40020225, DOI: 10.1146/annurev-immunol-082523-124415.Peer-Reviewed Original ResearchHumanized miceHuman hematopoiesisImmune responseImmune systemHumanized mouse modelHuman hematopoietic stemImmunocompromised murine hostsResident immune cellsHuman immune responseStudy human immunityHuman immune systemIntegration of multi-omicsHematopoietic stemImmune cell growthImmune cellsEngineered miceProgenitor cellsMouse modelImmunological diseasesMurine hostCancer treatmentPreclinical drugsHuman immunityMiceModel diseaseDissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing
Castellanos-Rueda R, Wang K, Forster J, Driessen A, Frank J, Martínez M, Reddy S. Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing. Science Advances 2025, 11: eadp4008. PMID: 39951542, PMCID: PMC11827634, DOI: 10.1126/sciadv.adp4008.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorT-cell phenotypeT cell responsesT cell activationCAR T cell phenotypesCAR T-cell biologyModulate T cell responsesT cell persistenceCAR-T therapySingle-cell sequencingT cell functionT cell biologyCorrelated in vitroT therapyT cellsAntigen receptorClinical outcomesCD40 costimulationCancer treatmentPhenotypeSignaling domainMembrane-proximal domainCostimulationCD40Screening approachThe Challenging Problems of Cancer and Serious Mental Illness
Grassi L, McFarland D, Riba M, Ferrara M, Zaffarami G, Belvederi Murri M, Cruciata M, Caruso R. The Challenging Problems of Cancer and Serious Mental Illness. Current Psychiatry Reports 2025, 27: 41-57. PMID: 39786658, PMCID: PMC11724792, DOI: 10.1007/s11920-024-01570-9.Peer-Reviewed Original ResearchConceptsSerious mental illnessProblem of cancerMental illnessGeneral populationPhysical health careRates of screeningMental health servicesHealth-care systemMedication side effectsHealth servicesOncology settingUnhealthy lifestyleHealth careCancer preventionStandard cancer treatmentHigher mortalitySomatic disordersCareVulnerable segmentsNegative outcomesIllnessOncologyCancer treatmentDelayed treatmentCancer
2024
Rectourethral fistula after perirectal spacer placement requiring pelvic exenteration
Shah Y, Lokeshwar S, Brutus N, Sterling J. Rectourethral fistula after perirectal spacer placement requiring pelvic exenteration. BMJ Case Reports 2024, 17: e263333. PMID: 39719384, DOI: 10.1136/bcr-2024-263333.Peer-Reviewed Original ResearchConceptsPelvic exenterationRectourethral fistulaSpacer placementRectal radiation doseRobotic pelvic exenterationProstate cancer treatmentManagement of complicationsImprove cancer controlRectal toxicityGastrointestinal toxicitySpacer useClinical benefitFecal diversionSevere complicationsPostmarketing dataPatient counselingCancer controlRadiation doseCancer treatmentSevere outcomesLack of evidenceEarly identificationExenterationPhysician techniqueFistulaTertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction
Gao X, Tang X, Tu Z, Yu J, Bao Y, Long G, Sheu W, Wu H, Liu J, Zhou J. Tertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction. Biomaterials 2024, 317: 123035. PMID: 39731842, PMCID: PMC11827167, DOI: 10.1016/j.biomaterials.2024.123035.Peer-Reviewed Original ResearchConceptsSurvival of tumor-bearing miceBrain tumorsEffective treatmentPenetrate brain tumorsEffective treatment of glioblastomaTumor-bearing micePrimary brain tumorTreatment of glioblastomaMitochondria-targeted effectsTreating glioblastomaCancer treatmentGlioblastomaEffective killingTherapeutic targetHexokinase inhibitorGBM cellsPyroptosis inductionMitochondriaTumorGlycyrrhetinic acidTargeting effectTreatmentPhysical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls
Sletten R, Slaaen M, Oldervoll L, Skjellegrind H, Benth J, Åstrøm L, Kirkevold Ø, Bergh S, Grønberg B, Rostoft S, Bye A, Mork P, Christiansen O. Physical Performance and Activity in Older Prostate Cancer Survivors in Comparison with Population-based Matched Controls. European Urology Open Science 2024, 71: 87-95. PMID: 39758854, PMCID: PMC11697607, DOI: 10.1016/j.euros.2024.11.005.Peer-Reviewed Original ResearchOlder prostate cancer survivorsPoor grip strengthProstate cancer survivorsPhysical performancePhysical functionCancer survivorsPhysical activityPopulation-basedGrip strengthSelf-reported physical activityGeneral populationOne-leg balancePhysical activity levelsPhysical activity indexCompare physical performanceOverall physical functionProstate cancer treatmentLong-term physical performanceOverall physical performancePopulation-based controlsCross-sectional studyGait speedCancer treatmentSPPB scoreHealth StudyInappropriate Denials for Radiation Therapy in Medicare Advantage Plans
Pasetsky J, Bhatt K, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans. International Journal Of Radiation Oncology • Biology • Physics 2024, 121: 871-874. PMID: 39551102, DOI: 10.1016/j.ijrobp.2024.11.063.Peer-Reviewed Original ResearchConceptsIntensity-modulated RTRadiation therapyStereotactic body radiation therapyHealth servicesMedicare Advantage plansMedicare-eligible patientsChi-square testRadiation oncologistsProstate cancerTreatment modalitiesBreast cancerCancer treatmentTherapyCancerRT servicesPolicy changesMedicaid Services websiteCoverage guidelinesDenial ratesMedical specialtiesCenters for Medicare & Medicaid Services websiteTreatmentDenialBrachytherapyProstateBaseline predictors associated with successful weight loss among breast cancer survivors in the Lifestyle, Exercise, and Nutrition (LEAN) study
Hoobler R, Puklin L, Harrigan M, Cartmel B, Li F, Sanft T, Ferrucci L, Irwin M, Playdon M. Baseline predictors associated with successful weight loss among breast cancer survivors in the Lifestyle, Exercise, and Nutrition (LEAN) study. Journal Of Cancer Survivorship 2024, 1-9. PMID: 39528779, DOI: 10.1007/s11764-024-01702-3.Peer-Reviewed Original ResearchBreast cancer survivorsClinically meaningful weight lossCancer survivorsWeight loss interventionCancer SurvivorsBreast cancer survivorsWeight loss successConclusionBreast cancer survivorsPrevention of weight gainAssociated with lower oddsHistory of weight gainHealthy body weightMultivariate logistic regressionCancer treatmentSuccessful weight lossBreast cancer treatmentIntervention armLower oddsResultsBaseline dataDesign of programsWeight lossLogistic regressionC-statisticWeight gainSurvivorsInterventionAssociation Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome
Linhares S, Schultz K, Coppersmith N, Esposito A, Leeds I, Pantel H, Reddy V, Mongiu A. Association Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome. Cancers 2024, 16: 3578. PMID: 39518019, PMCID: PMC11545659, DOI: 10.3390/cancers16213578.Peer-Reviewed Original ResearchLow anterior resection syndromeChemotherapy-induced peripheral neuropathyAnterior resection syndromeSystemic therapyRectal cancerPeripheral neuropathyAssociated with low anterior resection syndromeRetrospective review of patientsPlatinum-based chemotherapy agentsLow anterior resectionReview of patientsSphincter-preserving surgeryRectal cancer treatmentNeoadjuvant chemoradiationTumor distanceAnal vergeAnterior resectionRetrospective reviewChemotherapy-inducedChemotherapy agentsSide effectsCancer treatmentDebilitating conditionPatientsCIPNEligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer
Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, Nagar H, Delacroix S, Lerner S, Efstathiou J. Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. Bladder Cancer 2024, 10: 199-213. PMID: 39493817, PMCID: PMC11530036, DOI: 10.3233/blc-240036.Peer-Reviewed Original ResearchBladder cancer treatmentTransurethral resection of bladder tumorEastern Cooperative Oncology GroupTrimodality therapyLong-term outcomesClinical trialsCancer treatmentRadical cystectomySystemic therapyEligibility criteriaSecondary endpointsTrial eligibility criteriaBladder cancerMaximal transurethral resection of bladder tumorEndpoint definitionsAlternative to radical cystectomyResection of bladder tumorCo-primary end pointsConcurrent systemic therapyMaximal transurethral resectionPhase II/III clinical trialsLocalized bladder cancerEvent-free survivalCooperative Oncology GroupBladder cancer researchFOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H. FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types. Molecular Therapy Oncology 2024, 32: 200895. PMID: 39583007, PMCID: PMC11584611, DOI: 10.1016/j.omton.2024.200895.Peer-Reviewed Original ResearchImmunotherapy resistanceB cellsPoor response to immunotherapyExpression of Blimp-1Cancer typesResponse to immunotherapyDifferentiation of B cellsB cell subpopulationsAssociated with poor response to immunotherapyPredicting treatment responseAffecting treatment efficacyDiverse cancer typesImmunotherapy efficacyImmunotherapy patientsTumor microenvironmentTreatment responsePlasma cellsImmunotherapyImmunosuppressive effectsBlimp-1Spatial transcriptomic analysisTreatment efficacyOvercome resistanceCancer treatmentImmunofluorescence analysisInappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action
Pasetsky J, Kachnic L, Yu J, Horowitz D. Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s127. DOI: 10.1016/j.ijrobp.2024.07.230.Peer-Reviewed Original ResearchRadiation therapyCenters for Medicare & Medicaid ServicesTraditional MedicareMA plansLife-saving cancer treatmentStatistically significant higher rateGrowing body of literatureBody of literatureMA star ratingsSignificantly higher ratesMedicare AdvantageUnfavorable decisionsHospice careStarsImprove accessCancer treatmentDenialRT servicesServicesAppealStar ratingsGrowing bodyCenters for Medicare & Medicaid Services websiteMedicare Advantage plansTherapyThe American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging
Farjah F, Barta J, Wood D, Rivera M, Osarogiagbon R, Smith R, Mullett T, Rosenthal L, Henderson L, Detterbeck F, Silvestri G. The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging. Cancer 2024, 130: 4167-4176. PMID: 39347610, PMCID: PMC11585343, DOI: 10.1002/cncr.34627.Peer-Reviewed Original ResearchLung cancer stagingCancer stageGuideline recommendationsPerformance feedback mechanismsLung cancerPatient self-advocacyImproving lung cancer stagingCurrent health policyPractice guideline recommendationsCancer treatmentProfessional societiesStage lung cancerLung cancer survivalStage-appropriate therapyLevel of evidenceComparative-effectiveness studiesHealth policyHealth systemCancer survivalLow-to-moderateAccurate stagingRecommended 4Practice guidelinesSelf-advocacyMultidisciplinary expertsPerceptions of Delayed Alopecia Among Breast Cancer Survivors
Premji S, Ruddy K, Vierkant R, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Perceptions of Delayed Alopecia Among Breast Cancer Survivors. Clinical Breast Cancer 2024, 25: e170-e177. PMID: 39592290, PMCID: PMC11769767, DOI: 10.1016/j.clbc.2024.09.008.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryCancer survivorsChemotherapy recipientsStage I-III breast cancerI-III breast cancerBreast cancer diagnosisPersistent bothersome symptomsRespondents' median ageBreast cancer treatmentMental healthDistressing symptomsDisease RegistryCancer diagnosisCohort studyHair lossSurvivorsBreast cancerBothersome symptomsBreastRespondentsSurvey 6 yearsParticipantsBotherCancer treatmentResiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer
Presley C, Grogan M, Compston A, Hock K, Knauss B, Redder E, Arrato N, Lo S, Janse S, Benedict J, Hoyd R, Williams N, Hayes S, Wells-Di Gregorio S, Gill T, Allore H, Focht B, Quist M, Carbone D, Spakowicz D, Paskett E, Andersen B. Resiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer. Journal Of Geriatric Oncology 2024, 15: 101844. PMID: 39174449, PMCID: PMC11701799, DOI: 10.1016/j.jgo.2024.101844.Peer-Reviewed Original ResearchShort Physical Performance BatterySupportive care interventionsProgressive muscle relaxationPhysical therapyCare interventionsOlder adultsVirtual healthSelf-report measures of functional statusTwo-minute walk testPatient Health Questionnaire-9Functional statusMeasures of functional statusAdvanced lung cancerGeneralized Anxiety Disorder-7Physical Performance BatteryActivity monitor dataEQ-5D-5LEvaluated in-personParticipants' functional statusCancer treatmentHealth sessionsPerformance BatteryResistance bandsPost-interventionWalk testExercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)
Schmitz K, Brown J, Irwin M, Robien K, Scott J, Berger N, Caan B, Cercek A, Crane T, Evans S, Ligibel J, Meyerhardt J, Agurs-Collins T, Basen-Engquist K, Bea J, Cai S, Cartmel B, Chinchilli V, Demark-Wahnefried W, Dieli-Conwright C, DiPietro L, Doerksen S, Edelstein S, Elena J, Evans W, Ferrucci L, Foldi J, Freylersythe S, Furberg H, Jones L, Levine R, Moskowitz C, Owusu C, Penedo F, Rabin B, Ratner E, Rosenzweig M, Salz T, Sanft T, Schlumbrecht M, Spielmann G, Thomson C, Tjaden A, Weiser M, Yang S, Yu A, Perna F, Caan B, Anderson S, Bahia H, Castillo A, Feliciano E, Johnson K, Ross M, Weltzein E, Brown J, Albarado B, Compton S, Green T, Nash R, Nauta P, Welch M, Yang S, Meyerhardt J, Dieli-Conwright C, Nguyen D, Pena A, Spielmann G, Kim Y, Evans W, Bea J, Blew R, Crane T, Bhatti A, Clavon R, Erlandsen S, Freylersythe S, Hollander K, Lopez-Pentecost M, Penedo F, Rolle L, Rossi P, Schlumbrecht M, Wheeler M, Irwin M, Cao A, Cartmel B, Ferrucci L, Gottlieb L, Harrigan M, Li F, McGowan C, Puklin L, Ratner E, Sanft T, Zupa M, Berger N, Cerne S, Mills C, Conochan S, Hundal J, Owusu C, Ligibel J, Campbell N, DiGuglielmo K, Kemp W, Maples-Campbell C, Nguyen T, Oppenheim J, Tanasijevic A, Thomson C, Yung A, Basen-Engquist K, Loomba P, Chinchilli V, Schmitz K, Binder J, Doerksen S, Foldi J, Garrett S, Scalise R, Sobolewski M, White L, Scott J, Cercek A, Cai S, Cao S, Furberg H, Harrison J, Jones L, Lee C, Levine R, Michalski M, Moskowitz C, Novo R, Rabazzi J, Stoeckel K, Salz T, Weiser M, Yu A, Demark-Wahnefried W, Robien K, Evans S, DiPietro L, Duong B, Edelstein S, Helmchen L, Le D, McCleary C, Tjaden A, Wopat H, Rabin B, Perna F, Agurs-Collins T, Czajkowski S, Elena J, Nebeling L, Norton W. Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO). Journal Of The National Cancer Institute 2024, 117: 9-19. PMID: 39118255, PMCID: PMC11717426, DOI: 10.1093/jnci/djae177.Peer-Reviewed Original ResearchSelf-reported physical functionTreatment-related outcomesTreatment-related side effectsRisk of suboptimal outcomesExercise interventionOncology carePhysical functionNational Cancer InstituteNutrition ProgramIntervention effectsCommon Data ElementsExerciseCancer InstituteCommunity opportunitiesData elementsStandard of careInterventionCareCancer patientsNutritionRelative dose intensityOutcomesSuboptimal outcomesCancer treatmentChemotherapy relative dose intensityAnxiety and fear of cancer recurrence as predictors of subsequent pain interference in early cancer survivorship: Exploring the moderating roles of cognitive and emotional factors
Gnall K, Emrich M, Magin Z, Park C, Bellizzi K, Sanft T. Anxiety and fear of cancer recurrence as predictors of subsequent pain interference in early cancer survivorship: Exploring the moderating roles of cognitive and emotional factors. Journal Of Behavioral Medicine 2024, 47: 980-993. PMID: 39110352, DOI: 10.1007/s10865-024-00506-1.Peer-Reviewed Original ResearchFear of cancer recurrencePain interferenceCancer survivorsAssociated with greater pain interferenceGreater pain interferencePrimary cancer treatmentCancer recurrenceQuality of lifeCancer survivorshipLonger-term painSelf-report measuresEmotion regulation difficultiesCancer treatmentConsequence beliefsChronic beliefsCognitive/emotional factorsPsychological treatmentLongitudinal studyPotential moderatorsAnxietyRegulation difficultiesPainFollow-upEmotional factorsSurvivorsState-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitorsFusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria
Chen L, Shen J, Kang Z, Zhang Z, Zheng Z, Zhang L, Xiao Z, Zhang Q, Fang H, Zhou J, Wang Y, Yang Y, Liu Z, Chen Q. Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria. Chem 2024, 10: 1783-1803. DOI: 10.1016/j.chempr.2024.01.030.Peer-Reviewed Original ResearchBreast cancerRegression of established tumorsLung metastasis of breast cancerMetastasis of breast cancerBroad-spectrum antibioticsBreast cancer treatmentBreast cancer chemotherapyEstablished tumorsIntratumoral microbiomeF. nucleatumLung metastasesChemotherapy efficacyOvercome chemoresistanceCancer therapyPromote chemoresistanceCancer chemotherapyCancer treatmentBreastCancerDrug delivery carriersTumorChemoresistanceDelivery carriersNanovehiclesEfficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply